×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lymphoma Cancer

Kristie L. Kahl
In this episode, we spoke with a rare lymphoma survivor on how chimeric antigen receptor T-cell therapy saved her life.
Kristie L. Kahl
In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.

 
Kristie L. Kahl
Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.
Angela Hammack, B.S.N., RN, OCN
Extraordinary Healer® Award finalist Angela Hammack, B.S.N., RN, OCN, discussed how she began running marathons to raise awareness – and $100,000 – for cancer.
Jessica Skarzynski
Here are the top 5 CURE stories for March 2019.
Ryan Hamner
How being treated for an allergy to cats and persistence finally led to my diagnoses of Hodgkin's lymphoma.
Katie Kosko
Productivity loss among parent caregivers associated with poor health-related quality of life in pediatric advanced stage Hodgkin lymphoma. 
Ryan Hamner
In order to help others, this survivor and author must "bare all" to get his message out.
Jason M. Broderick and Katie Kosko
Treating younger patients with low-risk diffuse large B-cell lymphoma (DLBCL) with two fewer front-line cycles of standard treatment greatly reduced toxicity without sacrificing effi­cacy.
Jason M. Broderick
The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other